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1. Introduction 
Among the complications of inflammatory rheumatic diseases, amyloid A (AA) amyloidosis 
is one of the most severe because of its poor prognosis. AA amyloidosis commonly affects 
the kidney and the gastrointestinal tract, and is characterized by various clinical symptoms 
such as progressive proteinuria and renal dysfunction and failure. Control of the underlying 
disease, i.e. suppression of serum amyloid A (SAA) levels, is the most critical step in the 
treatment of AA amyloidosis. An immunosuppressant such as methotrexate, azathioprine, 
or cyclophosphamide, and moderate doses of prednisolone are commonly used to 
accomplish this. However, in some active cases, satisfactory suppression of SAA levels 
cannot be achieved, and the function of the affected organs deteriorates. The prognosis is 
usually poor for patients in advanced stages of AA amyloidosis. The major causes of death 
are renal failure and infection. Some retrospective studies and case reports have shown anti-
tumor necrosis factor (TNF) therapies to be useful against AA amyloidosis (Elkayam et al., 
2002; Fernándes-Nebro et al., 2010; Gottenberg et al., 2003; Kuroda et al., 2009; Nakamura 
et al., 2010). Although treatment with anti-TNF agents does reduce acute-phase reactants 
such as C-reactive protein (CRP) and SAA in chronic inflammatory diseases, unfortunately 
complete normalization of such acute-phase proteins is rarely observed. 
On the other hand, several case reports and a retrospective comparative study have shown 
that tocilizumab, an anti-human interleukin-6 (IL-6) receptor monoclonal antibody, has an 
excellent ability to suppress SAA levels and improve clinical symptoms of AA amyloidosis 
with marked lasting regression of AA protein deposits (Inoue et al., 2010; Kishida et al., 
2011; Nishida et al., 2009; Okuda & Takasugi, 2006; Okuda 2009; Sato et al., 2009; Ubara, 
2009). Treatment with tocilizumab could, therefore, represent an important therapeutic 
strategy for AA amyloidosis secondary to rheumatic diseases. 
2. Pathogenesis of AA amyloidosis in rheumatic diseases 
AA amyloidosis resulting from deposition of AA protein in the extracellular matrices of 
various organs may lead to multiple organ dysfunction, and the prognosis is usually poor in 
patients with advanced AA amyloidosis. 
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Although formerly chronic infections such as tuberculosis were listed as the principal cause 
of AA amyloidosis, most cases of AA amyloidosis at present are closely associated with 
chronic inflammatory diseases such as rheumatoid arthritis (RA) (Sasatomi et al., 2007). 
SAA, the precursor of AA protein, is highly amplified in the liver under the stimulation of 
inflammation-associated cytokines such as IL-6, TNF, and IL-1 (Yamada, 1999). Prolonged 
elevation of SAA is the major inciting factor for AA amyloidosis developing in chronic 
inflammatory diseases. The extensive and persistent production of SAA under chronic 
active inflammatory conditions is the critical prerequisite for AA amyloidosis fibrillogenesis, 
and approximately 10–15% of Japanese RA patients have AA amyloidosis deposits in their 
gastroduodenal mucosa as shown by endoscopic biopsy (Kobayashi et al., 1996). 
SAA is genetically polymorphic with four loci (SAA1, SAA2, SAA3, and SAA4) located on 
chromosome 11 (Yamada, 1999). The SAA gene products SAA1 and SAA2 are both elevated 
with acute inflammation and are therefore named acute-phase SAA. More than 90% of  
the precursor proteins of AA protein are derived from SAA1 (Liepnieks et al., 1995).  
SAA1 has several allelic variants, in which the exon 3 polymorphism generates  
three common isoforms in the Japanese population: SAA1.1:52Valine/57Alanine, 
SAA1.3:52Alanine/57Alanine, and SAA1.5:52Alanine/57Valine. It has been suggested that 
this polymorphism contributes to the susceptibility of the Japanese to RA-associated AA 
amyloidosis (Baba et al., 1995; Okuda et al., 1999; Moriguchi et al., 1999; Nakamura et al., 
2006); SAA1.3 may be a risk factor for AA amyloidosis, while SAA1.1 acts as a defense. 
SAA1.1, however, has been reported to be a risk factor in Caucasians (Booth et al., 1998), 
suggesting a racial difference concerning the contribution of exon 3 polymorphism to the 
pathogenesis of AA amyloidosis in RA. 
In animal model studies, elevated SAA was detected in ageing mice (Hsu et al., 1997), and 
organ extracts from aged mice had amyloid enhancing factor activity that accelerated 
experimental SAA production (Yokota et al., 1989). We examined the contributions of 
ageing to the induction of AA amyloidosis in RA in our large cohort (388 adult-onset RA 
patients with AA amyloidosis) including 144 patients who been analyzed for SAA1 
polymorphism. We identified ageing as an independent risk factor for the formation of AA 
amyloidosis complicating RA (Okuda et al., 2011). Figure 1 shows the pathogenetic cascade 
of AA amyloidosis in rheumatic diseases. 
3. Treatment of AA amyloidosis 
The most rational treatment of AA amyloidosis is just to inhibit the production of SAA, the 
precursor of the AA proteins. As evidence of this, Gillmore et al. (2001) used serum amyloid 
P (SAP) scintigraphy to evaluate the level of amyloid deposits in organs in patients with AA 
amyloidosis associated with inflammatory diseases such as RA. They reported that when 
the SAA concentration in the blood was less than 10 mg/L, the level of amyloid deposits in 
the organs decreased and the 10 year survival rate was good at about 90%, whereas in 
patients with SAA levels of 10 mg/L or higher, the 10-year survival rate was about 40%. 
Maintenance of SAA concentrations within the normal range correlated significantly with 
reduced amyloid deposition and improved prognosis. The same group investigated 374 
patients with AA amyloidosis and performed a more detailed analysis of the very close 
correlation between decreases in SAA concentration and improved survival prognosis. SAP 
scintigraphy revealed significant disappearance of AA protein in the low-concentration 
group compared with that in the high-concentration group. Control of the SAA 
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Fig. 1. SAA synthesis and pathogenesis of AA amyloidosis 
concentration was stressed as the most important parameter in amyloidosis treatment 
(Lachmann et al., 2007). Therefore, it is very important to inhibit as much as possible the 
activity of the underlying disease itself. Rheumatic diseases are the most common 
underlying diseases of AA amyloidosis, and in the treatment of rheumatic disease patients, 
biologics show higher efficacy than do conventional treatments and can be used in current 
routine clinical practice. Anti-cytokine treatment is especially useful but there are certain 
characteristics and problems involved, which are discussed in detail in the next section. 
Among other treatments—when immunosuppressants and biologics are not adequate 
because of problems such as chronic infections or organ damage—there are often cases 
where moderate doses of corticosteroids (prednisolone 10–20 mg) are necessary. Because 
rheumatic diseases often affect elderly patients over the long term, complications can 
include onset of severe infections and thoracic and lumbar vertebral compression fractures 
due to osteoporosis. 
For treatment of AA amyloidosis from a different standpoint, the organic solvent dimethyl 
sulfoxide (DMSO) is sometimes administered in an attempt to eliminate AA protein by 
increasing the degree of solubility of amyloid protein deposited in the tissues. Although not 
proven in controlled comparative studies, several case reports and case series reports 
suggesting its usefulness have appeared (Ravid et al., 1982, Gruys et al., 2005). 
Eprodisate, a mimetic of glycosaminoglycan that serves as the extracellular scaffold for 
amyloid deposits in tissues, is expected to show therapeutic effects because it prevents 
accumulation of AA protein. A multicenter randomized double-blind placebo-controlled 
study was conducted mainly in Europe and the United States. It was reported that the risk 
of decline of renal function was lowered by 42%; however, no significant differences were 
found in the risk of decreases in the progression to end-stage renal failure and mortality 
(Dember et al., 2007). Applications were filed with the FDA, etc. as an orphan drug but they 
were not approved, and an additional international study is now in progress—International 
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of 
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In the future we can expect to see the adjunctive or monotherapeutic use of biologics in 
patients who cannot undergo strong immunosuppressant treatment because of 
complications such as chronic infections. 
 
 
SAA: serum amyloid A; GAG: glycosaminoglycan 
Fig. 2. Treatment strategies for AA amyloidosis 
4. Treatment of AA amyloidosis with biologics 
At present, reports of efficacy in the treatment of AA amyloidosis by biologics have stressed 
anti-TNF therapy and anti-IL-6 therapy, both of which are anti-cytokine therapies. First, 
anti-TNF therapy will be explained, and then anti-IL-6 therapy, which is the core topic of 
this overview, will be explained in detail. 
4.1 Anti-TNF therapy 
Elkayam et al. (2002) first reported that nephrotic syndrome was rapidly improved using the 
anti-TNF antibody drug infliximab in patients with AA amyloidosis associated with RA. 
Thereafter, a multicenter study was performed in France, and Gottenberg et al. (2003) 
evaluated anti-TNF therapy for renal disorders in 15 patients with AA amyloidosis 
associated with inflammatory arthritis (10 patients were given infliximab, four were given 
etanercept, and one was given both agents). They observed decreased proteinuria or 
elevated glomerular filtration rate in three patients, no progression of renal disorders in five, 
and worsening or progression of renal dysfunction in seven patients. Anti-TNF therapy was 
effective in more than half of the patients with renal disorders (Gottenberg et al., 2003). Case 
reports and case series reports from many facilities then appeared showing the efficacy of 
this therapy against AA amyloidosis associated with chronic inflammatory diseases such as 
rheumatic diseases (Bosca et al., 2006; Drewe et al., 2004;Kobak et al., 2007; Smith et al., 
2004).  
In Japan, the efficacy of anti-TNF therapy has been reported in many papers and reports 
given at academic society meetings. Kuroda et al. (2009) and Nakamura et al. (2010) 
reported efficacy in a large number of patients over a short time. Kuroda et al. analyzed 
therapeutic results in 14 RA patients complicated with AA amyloidosis in whom RA 
treatment was effective (four were given infliximab and 10 were given etanercept; mean 
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observation period: 20.1 months). They found that 24-h creatinine clearance improved in 
three patients, was unchanged in five, and became worse in three. In a 24-h proteinuria 
assay, three patients showed decreased proteinuria, six were unchanged, and three became 
worse, indicating that progression of renal disorders was prevented in about 70% of 
patients. In nine patients subjected to serial gastroduoedenal biopsies, the level of amyloid 
deposits in the tissue was reported to decrease significantly (Kuroda et al., 2009). Nakamura 
et al. (2010) used etanercept to treat 14 Japanese patients who had the SAA1.3 allele and high 
susceptibility to AA amyloidosis (mean observation period: 19 months) and analyzed their 
renal function profiles. Significant improvements were found in RA disease activity, SAA 
concentrations, 24-h proteinuria levels, and serum albumin levels. Creatinine was analyzed 
by grouping patients into those with creatinine levels of less than 2.0 mg/dL at introduction 
of etanercept and those with creatinine levels of 2.0 mg/dL or higher; no improvement in 
creatinine levels was reported in the 2.0 mg/dL or higher group. Nakamura et al. (2010) 
stressed the necessity of introducing etanercept treatment in the early stages of declining 
renal function. 
Fernándes-Nebro et al. (2010) conducted a multicenter case-control study of the long-term 
treatment (mean observation period: 2.9 years) of many patients with an immune-mediated 
inflammatory disease complicated with AA amyloidosis. They evaluated 36 patients (29 
given infliximab and seven given etanercept). A kidney response was observed in 12 of 22 
patients (54.5%), kidney progression was observed in 6 of 36 patients (17%), and kidney 
amyloidosis remained stable in 16 of 36 patients (44%), which were considered good results. 
However, although proteinuria was significantly improved (p < 0.001), serum creatinine 
levels (p = 0.783) and creatinine clearance (p = 0.721) showed no significant differences 
before and after treatment. Significant improvement was found in inflammatory markers, 
but the normal range was not achieved. The four-year continuation rate of anti-TNF agents 
was 52%, and no differences from the control group were observed. Severe proteinuria was 
a risk factor for treatment response and continuation and for survival. The incidences of 
adverse drug reactions also showed no differences from the control group, but the 
frequencies of septicemia and severe infections were three times as high. Eight patients in 
the amyloid group and one in the control group of rheumatic disease patients without AA 
amyloidosis died, and an increased risk of infections was noted in the amyloid group in 
terms of safety (Fernándes-Nebro et al., 2010). 
The above reports indicate that anti-TNF therapy is effective in patients with rheumatic 
diseases complicated with AA amyloidosis, but in patients with progressive renal 
dysfunction the possibility of irreversible changes is as high as in other chronic renal 
diseases and the risk of infections increases during the period up to multiple organ failure. 
Therefore, the utmost caution is necessary after introducing anti-TNF therapy and 
confirming the reduction in inflammatory markers, showing that the response to the 
underlying disease treatment is favorable. 
4.2 Anti-IL-6 therapy 
4.2.1 IL-6 and the mode of action of tocilizumab 
IL-6 has a unique receptor system: although IL-6 receptor (IL-6R) specifically binds to IL-6, it 
is not directly involved in signal transduction. IL-6 forms a complex by binding to IL-6R on 
the cell membrane, which then combines with gp130, which also resides on the cell 
membrane, forming a homodimer and initiating intracellular signal transduction. 
Furthermore, IL-6R also exists in soluble form. After forming a complex with IL-6, soluble 
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IL-6R (sIL-6R) can also combine with gp130 on the cell membrane and enable signaling 
(Ward et al., 1994). sIL-6R is present in the blood of healthy individuals at a concentration of 
several tens of ng/mL, and if cells express gp130, IL-6 signaling can take place, even in the 
absence of IL-6R expression on the cell membrane. Reflecting this characteristic, the effects 
of IL-6 are diverse, and it is thought to have an extensive regulatory role, with involvement 
in the immune response, inflammation, bone metabolism, hematopoiesis, and the 
neuroendocrine system (Figure3). 
 
 
Constitutive overproduction of interleukin-6, a pleiotropic cytokine that regulates the immune system, 
inflammation, hematopoiesis, and bone metabolism, is thought to play pathologic roles in rheumatic 
diseases. VEGF: vascular endothelial growth factor; ICAM-1: intercellular adhesion molecule-1; 
Th17: interleukin-17-producing CD4+ T cell; Treg: CD4+CD25+ regulatory T cell; RF: rheumatoid factor; 
CRP: C-reactive protein; SAA: serum amyloid A; RBC: red blood cell 
Fig. 3. Pathological roles of interleukin-6 in rheumatic diseases  
Tocilizumab is a recombinant monoclonal antibody that has been humanized by 
complementarity-determining region (CDR) grafting of a murine anti-human IL-6R 
antibody onto human IgG1. Tocilizumab inhibits the induction of IL-6-mediated biological 
activity in cells that have expressed both membrane-bound IL-6R and gp130 molecules, and 
also inhibits the induction of biological activity mediated by IL-6/sIL-6R complex formation 
in cells that express gp130 alone. Furthermore, since tocilizumab has the capacity to 
dissociate IL-6/IL-6R complexes that have already formed (Mihara et al., 2005), it exhibits an 
extremely effective blocking action on IL-6 signal transduction (Figure 4). 
4.2.2 Pivotal role of IL-6 in SAA synthesis 
The signal transduction and transcription mechanisms of TNF-alpha, IL-1-beta, and IL-6 in 
the production of SAA have become clear. In a study using HepG2 cells, a cell line derived 
from hepatocytes, weak expression of SAA1 and SAA2 mRNA was induced by stimulation 
with IL-6 alone, but almost no expression was induced by stimulation with either IL-1-beta 
or TNF-alpha alone. However, synergistic induction of expression was observed by 
costimulation with IL-6 and IL-1-beta or with IL-6 and TNF-alpha (Hagihara et al., 2004). 
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Fig. 4. Signal transduction of the interleukin-6/interleukin-6 receptor complex via gp130 and 
the mechanism of signal transduction blockade by tocilizumab. 
Activation of STAT3 by IL-6 stimulation is essential in the production of SAA, and it is clear 
that SAA expression is strengthened by supplementation of NF-kappaBp65 activity by 
stimulation with TNF-alpha or IL-1-beta (Hagihara et al., 2005). Clinically, TNF inhibitors 
reduce SAA levels, but complete normalization is rare. However, tocilizumab can normalize 
SAA levels in almost all patients in whom a sufficient concentration of tocilizumab is 
maintained in the blood. 
4.2.3 AA amyloidosis treatment by anti-IL-6 receptor therapy 
Tocilizumab, a humanized anti-IL-6 receptor antibody drug, was approved in Japan in 2008 
for RA, polyarticular juvenile idiopathic arthritis (JIA), and systemic JIA.  At present, 
tocilizumab is the most effective agent against AA amyloidosis by the mechanism of action 
based on SAA reduction described above. Almost all patients undergoing anti-IL-6 therapy 
are those who can maintain tocilizumab blood concentrations, and SAA normalization is 
possible. In contrast, although it is already clear from routine clinical practice that anti-TNF 
therapy does decrease SAA, the percentage of patients undergoing anti-TNF therapy who 
achieve complete normalization is not high. And recently tocilizumab is reported to be very 
effective in many autoimmune and inflammatory diseases including auto-inflammatory 
diseases such as TNF receptor associated periodic syndrome which may cause AA 
amyloidosis (Tanaka, 2011). 
Before its approval in 2008, we provided compassionate use of tocilizumab to a patient with 
life-threatening JIA complicated with rapidly progressing AA amyloidosis in whom many 
drugs were ineffective. SAA was completely normalized by early administration of 
tocilizumab, digestive tract symptoms (intractable diarrhea) disappeared, renal symptoms 
(proteinuria and renal dysfunction) were normalized, and AA protein showed marked 
disappearance from the tissues. The clinical course and usefulness in this case have been 
reported (Okuda & Takasugi, 2006) (Figures 5 & 6). 
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A: Before tocilizumab therapy was started, the appearance of the mucosa in the second portion of the 
duodenum was coarse, nodular, irregular, edematous, and reddish.  
B: Before tocilizumab therapy, the appearance of the mucosa in the antrum of the stomach was coarse, 
with reddish and edematous changes.  
C and D: After 18 months of tocilizumab therapy, no abnormality was observed in the second potion of 
the duodenum or in the antrum of the stomach, respectively  
(Quoted from: Okuda Y, Takasugi K. (2006). Successful use of a humanized anti-interleukin-6 receptor 
antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. 
Arthritis Rheum. Vol. 54, No. 9, pp. 2997–3000)  
Fig. 5. Results of endoscopic examination before and after tocilizumab therapy (Case 1) 
We have also reported that during a clinical study on tocilizumab, in a group of patients 
with RA complicated with AA amyloidosis, AA protein deposits disappeared from the 
digestive tract and renal function improved (Okuda, 2009). Figure 7 shows improved 
histological findings in a patient with RA complicated with AA amyloidosis obtained 
during the clinical study on tocilizumab. Many papers presented at meetings and case 
www.intechopen.com
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Massive amyloid A protein deposits were observed in duodenal mucosa and submucosa before the start 
of tocilizumab therapy.  
 
 
Lower: Marked regression of amyloid A protein deposits was seen in duodenal mucosa and submucosa 
after tocilizumab treatment. (Congo red stained; 200× magnification)  
(Quoted from: Okuda Y, Takasugi K. (2006). Successful use of a humanized anti-interleukin-6 receptor 
antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. 
Arthritis Rheum. Vol. 54, No. 9, pp. 2997–3000) 
Fig. 6. Results of gastrointestinal biopsy before and after tocilizumab therapy (Case 1) 
reports have since appeared suggesting the wide-ranging usefulness of tocilizumab in 
treating rheumatic diseases complicated with AA amyloidosis (Inoue et al., 2010; Kishida 
et al., 2011; Sato et al., 2009). 
Even in patients that have switched to tocilizumab because of the insufficient effect or lack 
of effect of anti-TNF agents, it is reported that treatment with tocilizumab has marked 
effects on gastrointestinal disorders and histology (Nishida et al., 2009) and improves renal 
dysfunction (Ubara, 2009). Expectations related to the usefulness of tocilizumab are high. 
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Massive amyloid A protein deposits were observed in duodenal mucosa and submucosa before the start 
of tocilizumab therapy. (Creatinine: 1.4 mg/dL)  
 
 
Complete regression of amyloid A protein deposits was seen in duodenal mucosa after 6.5 years of 
tocilizumab treatment. (Creatinine: 0.85 mg/dL) (Congo red stained; 200× magnification) 
Fig. 7. Gastrointestinal biopsy before and after tocilizumab therapy (Case 2) 
However, an all-case post-marketing survey for tocilizumab (Koike et al., 2010) found that, 
among patients with progressive renal disorders with multiple organ failure in whom 
tocilizumab was used for life-saving purposes, complications such as infections and deaths 
were reported. Therefore, considerable caution is required when tocilizumab is used. When 
considered from the standpoint of immunosuppression, it is desirable to use tocilizumab 
from an earlier stage when the risk of infections is lower, in the same way as anti-TNF 
therapy. At present, a multicenter investigator-initiated prospective clinical study 
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comparing clinical and histological improvements in the tocilizumab group with a control 
group is underway in Japan, and evidence that proves more objectively the usefulness of 
tocilizumab exceeding that of other drugs is expected. 
5. Conclusion 
Tocilizumab has an excellent ability to suppress SAA levels and improve clinical symptoms 
of AA amyloidosis with marked lasting regression of AA protein deposits. Treatment with 
tocilizumab could, therefore, represent an important therapeutic strategy for AA 
amyloidosis secondary to rheumatic diseases. 
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